Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 23, 2021, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dabigatran Etexilate Capsules, 150 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 23, 2021, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dabigatran Etexilate Capsules, 150 mg".